Key Points
- CFO James Edgemond sold 10,000 shares of United Therapeutics on June 11 at an average price of $549.29, totaling about $5.49 million. After the sale, he still held 18,876 shares, a 34.63% reduction in his position.
- The filing notes that Edgemond has been selling shares repeatedly in recent weeks, including multiple 10,000-share sales throughout May and early June. These transactions suggest sustained insider selling activity.
- United Therapeutics shares were trading around $545.96, near the upper end of their 52-week range of $272.12 to $609.35. The company recently missed quarterly earnings estimates, posting $5.82 EPS versus $7.00 expected.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $549.29, for a total value of $5,492,900.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,368,398.04. This represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
James Edgemond also recently made the following trade(s):
- On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00.
- On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00.
- On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total value of $5,478,700.00.
- On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00.
- On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
- On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
- On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.
- On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00.
- On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total value of $5,730,300.00.
- On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
United Therapeutics Stock Up 0.1%
Shares of United Therapeutics stock opened at $545.96 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The business has a 50-day moving average price of $566.75 and a 200 day moving average price of $521.34. The firm has a market cap of $23.18 billion, a PE ratio of 20.15, a P/E/G ratio of 1.78 and a beta of 0.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analysts' expectations of $797.40 million. During the same quarter last year, the firm posted $6.63 earnings per share. United Therapeutics's quarterly revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC lifted its holdings in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC lifted its holdings in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock valued at $624,508,000 after acquiring an additional 295,221 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock valued at $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Finally, Darwin Global Management Ltd. acquired a new position in United Therapeutics in the third quarter valued at approximately $317,617,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have commented on UTHR shares. Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective for the company. Finally, Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $619.42.
Get Our Latest Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
